Akèy › Dematit atopik (Ekzema)
Etid klinik pou Dematit atopik (Ekzema) ap rekrite nan Etazini
62 etid pou Dematit atopik (Ekzema) ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY13 etid
- Washington, DC11 etid
- Los Angeles, CA11 etid
- San Diego, CA10 etid
- San Antonio, TX10 etid
- Birmingham, AL9 etid
- Miami, FL9 etid
- Troy, MI8 etid
- Dallas, TX8 etid
- Sacramento, CA8 etid
- Huntington Beach, CA8 etid
- Pittsburgh, PA7 etid
- Indianapolis, IN7 etid
- Tampa, FL7 etid
- Sugar Land, TX6 etid
- Phoenix, AZ6 etid
- Santa Clarita, CA6 etid
- Santa Monica, CA6 etid
- Chicago, IL6 etid
- Philadelphia, PA6 etid
- Las Vegas, NV5 etid
- St. Petersburg, FL5 etid
- Charleston, SC5 etid
- Portland, OR5 etid
- Little Rock, AR5 etid
- Fremont, CA4 etid
- Miami Gardens, FL4 etid
- Portsmouth, NH4 etid
- Ann Arbor, MI4 etid
- Fargo, ND4 etid
- Baltimore, MD4 etid
- Louisville, KY4 etid
- Newton, MA4 etid
- Arlington, TX4 etid
- San Francisco, CA4 etid
- Coral Springs, FL4 etid
- Harrisburg, PA4 etid
- Cleveland, OH4 etid
- Morgantown, WV4 etid
- Detroit, MI3 etid
Pa eta
- Alabama9 etid
- Arizona7 etid
- Arkansas8 etid
- Colorado4 etid
- Florid18 etid
- Georgia9 etid
- Idaho4 etid
- Illinois10 etid
- Indiana9 etid
- Kalifòni30 etid
- Kentucky4 etid
- Maryland16 etid
- Massachusetts6 etid
- Michigan14 etid
- Missouri7 etid
- Nebraska4 etid
- Nevada6 etid
- New Hampshire5 etid
- New Jersey3 etid
- New York16 etid
- North Carolina8 etid
- North Dakota4 etid
- Ohio10 etid
- Oregon6 etid
- Pennsylvania13 etid
- South Carolina10 etid
- Texas18 etid
- Utah4 etid
- Virginia5 etid
- Washington3 etid
- West Virginia4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Ap rekriteFaz 1
Laj 12 a 120 · Tout sèks · Mizajou Oct 1, 2026 · NCT07262983This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Ap rekriteEtid obsèvasyon
Laj 12 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07290803A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 72 · Tout sèks · Mizajou Sep 29, 2026 · NCT06808477Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 29, 2026 · NCT07453602Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06947993Effects of Treatments on Atopic Dermatitis
Ap rekriteFaz 2Volontè an sante akeyi
Laj 2 a 50 · Tout sèks · Mizajou Sep 28, 2026 · NCT01631617A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Ap rekriteFaz 3
Laj 2 a 11 · Tout sèks · Mizajou Sep 25, 2026 · NCT06807281First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 25, 2026 · NCT07527923Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07298395A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Ap rekriteFaz 2
Laj 18 a 64 · Tout sèks · Mizajou Sep 25, 2026 · NCT07216027A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07003425Natural History and Genetics of Food Allergy and Related Conditions
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 99 Years · Tout sèks · Mizajou Sep 22, 2026 · NCT02504853Metabolic Profiling of Immune Responses in Immune-mediated Diseases
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Sep 22, 2026 · NCT04864886Studies of Skin Microbes in Healthy People and in People With Skin Conditions
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 100 · Tout sèks · Mizajou Sep 16, 2026 · NCT00605878Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
Ap rekriteEtid obsèvasyon
Laj 12 a 89 · Tout sèks · Mizajou Sep 15, 2026 · NCT07645820The Impact of Dietary Salt on the Severity of Eczema
Ap rekriteFaz 4Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT07447063The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease
Ap rekriteFaz 4Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07487831Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis
Ap rekrite
Laj 13 a 17 · Tout sèks · Mizajou Sep 8, 2026 · NCT07746427A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07765888A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07223697A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
Ap rekriteFaz 2/3
Laj 18 a 80 · Tout sèks · Mizajou Sep 4, 2026 · NCT07355075A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Aug 28, 2026 · NCT07599813Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis
Ap rekriteFaz 2
Laj 3 a 21 · Tout sèks · Mizajou Aug 26, 2026 · NCT03835767CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT04504955Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
Ap rekriteEtid obsèvasyon
Laj 12 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06899204Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.